India's health ministry reportedly is drafting a requirement that pharmaceuticals carry barcodes at the primary level of packaging.
MicroConstants China has signed a licensing agreement to gain the global rights for the development of AA98 antibody drug candidates from the Institute of Biophysics of the Chinese Academy of Sciences in a unique deal between academia and local industry.
When the just-ended New York negotiations failed to resolve drug-patenting and other intellectual property issues, the focus shifted to a ministerial-level meeting of the Trans-Pacific Partnership expected to take place in March.
SINGAPORE-- India's government is getting into the generic drug business. The state reportedly will launch its own brand, "Jan Aushadhi," on July 1, planning to sell up to 504 drugs on its "essential" list in direct competition with commercial drugmakers.
France's Sanofi has taken dramatic steps to increase its diabetes-related presence in India with shades of Viehbacher plans.
SINGAPORE-- As soon as the Delhi High Court revived Gilead Sciences' patent hopes for Sovaldi, a new actor has come on the scene: Sankalp Rehabilitation Trust, which has joined three other plaintiffs in opposing the new patent.
Dr. Reddy's Laboratories is weighing a shift away from its Srikakulam facility in southern India where some of its key active pharmaceutical ingredients are produced and which is under an FDA investigation.
A Pfizer plant in Ireland that was slated to close last year is still running strong, as sales of blockbuster cholesterol drug Lipitor remain vibrant in some parts of the world three years after losing its U.S. patent.
India has long been a major player in the development and manufacturing of treatments, but more and more drugmakers are outsourcing the monitoring of on-the-market drugs to vendors in the country.
Mylan will pay $750 million in cash to buy the women's healthcare businesses from India's Famy Care, placing it as the top seller of contraceptives in emerging markets.